Review Finds FDA Approval of Digital Antipsychotic Misguided
The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.
Medication Mechanization: Microchip Sensors in Abilify to Increase Medication Compliance
I felt a chill go through my body when I read that the FDA has agreed to review for possible approval in early 2016 a new form of the drug Abilify that contains a microchip sensor capable of sending a message that indicates the exact time a tablet dissolves in the stomach. The message is recorded by a skin patch - along with data such as the person’s body angle and activity patterns - and, according to a press release from Proteus Digital Health, the developer of the device, “this information is recorded and relayed to patients on a mobile phone or other Bluetooth-enabled device, and only with their consent, to their physician and/or their caregivers.”